Literature DB >> 9759834

Detection of a high frequency of virus-specific CD4+ T cells during acute infection with lymphocytic choriomeningitis virus.

S M Varga1, R M Welsh.   

Abstract

Lymphocytic choriomeningitis virus (LCMV), like many viruses, induces a profound activation and expansion of CD8+ T cells. In contrast, CD4+ T cells do not increase in total number during the acute infection. We show here that mice infected with LCMV have a low but detectable frequency (<1/300) of CD4+ T cells, as detected by IL-2 production in limiting dilution assays, to each of two class II peptides during the peak of the acute LCMV response and into long-term memory. However, during the peak of the acute CD4+ T cell response, >20% of the CD4+ T cells secreted IFN-gamma after stimulation with PMA and ionomycin, and >10% of the CD4+ T cells secreted IFN-gamma after stimulation with the LCMV peptides. Thus, these new sensitive assays reveal a heretofore unappreciated, yet profound Ag-specific CD4+ T cell response during viral infections.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9759834

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  30 in total

1.  An inverse relationship between T cell receptor affinity and antigen dose during CD4(+) T cell responses in vivo and in vitro.

Authors:  W Rees; J Bender; T K Teague; R M Kedl; F Crawford; P Marrack; J Kappler
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-17       Impact factor: 11.205

2.  CD4+ T-cell effectors inhibit Epstein-Barr virus-induced B-cell proliferation.

Authors:  S Nikiforow; K Bottomly; G Miller
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

Review 3.  T cell responses to viral infections: lessons from lymphocytic choriomeningitis virus.

Authors:  Aaruni Khanolkar; Michael J Fuller; Allan J Zajac
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

4.  Mapping and restriction of a dominant viral CD4+ T cell core epitope by both MHC class I and MHC class II.

Authors:  Dirk Homann; Hanna Lewicki; David Brooks; Jens Eberlein; Valerie Mallet-Designé; Luc Teyton; Michael B A Oldstone
Journal:  Virology       Date:  2007-02-21       Impact factor: 3.616

5.  Virally activated CD8 T cells home to Mycobacterium bovis BCG-induced granulomas but enhance antimycobacterial protection only in immunodeficient mice.

Authors:  Laura H Hogan; Dominic O Co; Jozsef Karman; Erika Heninger; M Suresh; Matyas Sandor
Journal:  Infect Immun       Date:  2006-12-18       Impact factor: 3.441

6.  CD11a and CD49d enhance the detection of antigen-specific T cells following human vaccination.

Authors:  Allison F Christiaansen; Upasna Gaur Dixit; Rhea N Coler; Anna Marie Beckmann; Steven G Reed; Patricia L Winokur; M Bridget Zimmerman; Steven M Varga; Mary E Wilson
Journal:  Vaccine       Date:  2017-06-27       Impact factor: 3.641

7.  Sustained high frequencies of specific CD4 T cells restricted to a single persistent virus.

Authors:  Martina Sester; Urban Sester; Barbara Gärtner; Boris Kubuschok; Matthias Girndt; Andreas Meyerhans; Hans Köhler
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

8.  Increased protection from vaccinia virus infection in mice genetically prone to lymphoproliferative disorders.

Authors:  Mina O Seedhom; Keisha S Mathurin; Sung-Kwon Kim; Raymond M Welsh
Journal:  J Virol       Date:  2012-03-21       Impact factor: 5.103

9.  PC61 (anti-CD25) treatment inhibits influenza A virus-expanded regulatory T cells and severe lung pathology during a subsequent heterologous lymphocytic choriomeningitis virus infection.

Authors:  Anke R M Kraft; Myriam F Wlodarczyk; Laurie L Kenney; Liisa K Selin
Journal:  J Virol       Date:  2013-09-18       Impact factor: 5.103

10.  IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation.

Authors:  Shlomo Z Ben-Sasson; Jane Hu-Li; Juan Quiel; Stephane Cauchetaux; Maya Ratner; Ilana Shapira; Charles A Dinarello; William E Paul
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.